Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring

Creator(s)

Abbey Elsbernd, Children's Mercy Kansas CityFollow
Boutaina Boulouadnine
Atif Ahmed, Children's Mercy Kansas City
Midhat S. Farooqi, Children's Mercy HospitalFollow
Tracy L. Sandritter, Children's Mercy HospitalFollow
Valentina Shakhnovich, Children's Mercy HospitalFollow
Darius Blanding, Children's Mercy Kansas CityFollow
Jean-Baptiste Demoulin
Joel Thompson, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

10-2022

Identifier

DOI: 10.1200/PO.22.00250

Journal Title

JCO Precis Oncol

Volume

6

First Page

2200250

Last Page

2200250

Recommended Citation

Elsbernd A, Boulouadnine B, Ahmed A, et al. Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring. JCO Precis Oncol. 2022;6:e2200250. doi:10.1200/PO.22.00250